Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-06-30

AUTHORS

J S Thompson Coon, Z Liu, M Hoyle, G Rogers, C Green, T Moxham, K Welch, K Stein

ABSTRACT

Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-α)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63–1.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. More... »

PAGES

238-243

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167

DOI

http://dx.doi.org/10.1038/sj.bjc.6605167

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013222336

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19568242


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson Coon", 
        "givenName": "J S", 
        "id": "sg:person.0762650054.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650054.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Z", 
        "id": "sg:person.01265262475.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265262475.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoyle", 
        "givenName": "M", 
        "id": "sg:person.0647332044.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647332044.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rogers", 
        "givenName": "G", 
        "id": "sg:person.01174312663.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "C", 
        "id": "sg:person.01262712354.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262712354.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moxham", 
        "givenName": "T", 
        "id": "sg:person.0607771575.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607771575.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK", 
          "id": "http://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Welch", 
        "givenName": "K", 
        "id": "sg:person.01225701373.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225701373.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "K", 
        "id": "sg:person.01054372611.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2407-6-293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045174638", 
          "https://doi.org/10.1186/1471-2407-6-293"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-9-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011234840", 
          "https://doi.org/10.1186/1471-2407-9-34"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-06-30", 
    "datePublishedReg": "2009-06-30", 
    "description": "Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-\u03b1 (IFN-\u03b1)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-\u03b1) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63\u20131.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605167", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "101"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "renal cell carcinoma", 
      "progression-free survival", 
      "advanced metastatic renal cell carcinoma", 
      "cell carcinoma", 
      "clinical trials", 
      "indirect comparison", 
      "median progression-free survival", 
      "first-line treatment", 
      "effects of sunitinib", 
      "systematic literature search", 
      "further relevant studies", 
      "licensed indication", 
      "overall survival", 
      "clinical effectiveness", 
      "common comparator", 
      "STUDY SELECTION", 
      "bevacizumab", 
      "new agents", 
      "sunitinib", 
      "IFN", 
      "electronic databases", 
      "systematic review", 
      "literature search", 
      "relevant studies", 
      "data extraction", 
      "survival", 
      "treatment", 
      "carcinoma", 
      "conference proceedings", 
      "trials", 
      "patients", 
      "study", 
      "evidence", 
      "Win BUGS", 
      "quality assessment", 
      "intervention", 
      "reviewers", 
      "indications", 
      "review", 
      "agents", 
      "assessment", 
      "comparator", 
      "database", 
      "criteria", 
      "comparison", 
      "effect", 
      "significant advantages", 
      "search", 
      "use", 
      "combination", 
      "data", 
      "bibliography", 
      "effectiveness", 
      "validation", 
      "disagreement", 
      "accordance", 
      "proceedings", 
      "selection", 
      "online interface", 
      "discussion", 
      "Europe", 
      "extraction", 
      "terms", 
      "advantages", 
      "Bayesian Markov chain Monte Carlo", 
      "BUGS", 
      "interface", 
      "Markov chain Monte Carlo", 
      "paper", 
      "Monte Carlo"
    ], 
    "name": "Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness", 
    "pagination": "238-243", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013222336"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605167"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19568242"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605167", 
      "https://app.dimensions.ai/details/publication/pub.1013222336"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_489.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605167"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      112 URIs      102 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605167 schema:about N0f85a8e35cc745e4bb07c941412adf68
2 N1400d7c7c0f643ab8070470578dd97e4
3 N1a0c9c32e61a4169b329919d5ad396ec
4 N2d4b4456b9754a91be3c3e0a4c95c58a
5 N3e6c531fd17c4b7a808886bfdf69ebe6
6 N40fbcac1c684402eb6ad44008e7f1d98
7 N5b18bd3335164b20a0e4273956ae14b5
8 N77291c9c8709465ba1d06a94946c7495
9 Nb83c384954ef4bdba387932356c87e8e
10 Nc1e47edf18bb474da5c498229e8b4436
11 Nd2fcd8c5bf784ddca3a78cfbe20e40ab
12 Ne59ee9519c204fa59618b904c2a15b82
13 Ne7fde29ac0474cf9a1e2d081910c1f31
14 Ned5d404bf6774e8194f81822d75e9c54
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N365016f84da548eb86377e8a1c63a2ad
18 schema:citation sg:pub.10.1186/1471-2407-6-293
19 sg:pub.10.1186/1471-2407-9-34
20 schema:datePublished 2009-06-30
21 schema:datePublishedReg 2009-06-30
22 schema:description Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-α)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63–1.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N38e5e9d052e740c9abc938bdd874d2f0
26 N92bc4b1e18214da5801bb7b4cbdb2527
27 sg:journal.1017082
28 schema:keywords BUGS
29 Bayesian Markov chain Monte Carlo
30 Europe
31 IFN
32 Markov chain Monte Carlo
33 Monte Carlo
34 STUDY SELECTION
35 Win BUGS
36 accordance
37 advanced metastatic renal cell carcinoma
38 advantages
39 agents
40 assessment
41 bevacizumab
42 bibliography
43 carcinoma
44 cell carcinoma
45 clinical effectiveness
46 clinical trials
47 combination
48 common comparator
49 comparator
50 comparison
51 conference proceedings
52 criteria
53 data
54 data extraction
55 database
56 disagreement
57 discussion
58 effect
59 effectiveness
60 effects of sunitinib
61 electronic databases
62 evidence
63 extraction
64 first-line treatment
65 further relevant studies
66 indications
67 indirect comparison
68 interface
69 intervention
70 licensed indication
71 literature search
72 median progression-free survival
73 metastatic renal cell carcinoma
74 new agents
75 online interface
76 overall survival
77 paper
78 patients
79 proceedings
80 progression-free survival
81 quality assessment
82 relevant studies
83 renal cell carcinoma
84 review
85 reviewers
86 search
87 selection
88 significant advantages
89 study
90 sunitinib
91 survival
92 systematic literature search
93 systematic review
94 terms
95 treatment
96 trials
97 use
98 validation
99 schema:name Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
100 schema:pagination 238-243
101 schema:productId N3723760a6d0b4d35bb333f48f16e69db
102 N753b0eb9867f4b9a817c0d815974ca31
103 Nc1160cca1b994d4a9756240f6ad09464
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013222336
105 https://doi.org/10.1038/sj.bjc.6605167
106 schema:sdDatePublished 2022-10-01T06:35
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N7d049ce2d737422fb03e2feb79710e4f
109 schema:url https://doi.org/10.1038/sj.bjc.6605167
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N0f85a8e35cc745e4bb07c941412adf68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 N1400d7c7c0f643ab8070470578dd97e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Randomized Controlled Trials as Topic
118 rdf:type schema:DefinedTerm
119 N1a0c9c32e61a4169b329919d5ad396ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antibodies, Monoclonal
121 rdf:type schema:DefinedTerm
122 N1bff15b719444435a68b53e52a2ed655 rdf:first sg:person.0647332044.69
123 rdf:rest Nc7bb00b2c9bd4e80bae37e0180d82708
124 N21c5f0e6273647b8b4fba5347b685d11 rdf:first sg:person.01262712354.34
125 rdf:rest Nbe65efe6a904432f946ecb5f5c242123
126 N2d4b4456b9754a91be3c3e0a4c95c58a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Kidney Neoplasms
128 rdf:type schema:DefinedTerm
129 N2ff6d1f158c748149374a336276cb939 rdf:first sg:person.01054372611.40
130 rdf:rest rdf:nil
131 N365016f84da548eb86377e8a1c63a2ad rdf:first sg:person.0762650054.31
132 rdf:rest Nf634c063da2044af9bb8b0f9eb2683f5
133 N3723760a6d0b4d35bb333f48f16e69db schema:name dimensions_id
134 schema:value pub.1013222336
135 rdf:type schema:PropertyValue
136 N38e5e9d052e740c9abc938bdd874d2f0 schema:issueNumber 2
137 rdf:type schema:PublicationIssue
138 N3e6c531fd17c4b7a808886bfdf69ebe6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pyrroles
140 rdf:type schema:DefinedTerm
141 N40fbcac1c684402eb6ad44008e7f1d98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Indoles
143 rdf:type schema:DefinedTerm
144 N5b18bd3335164b20a0e4273956ae14b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Sunitinib
146 rdf:type schema:DefinedTerm
147 N753b0eb9867f4b9a817c0d815974ca31 schema:name pubmed_id
148 schema:value 19568242
149 rdf:type schema:PropertyValue
150 N77291c9c8709465ba1d06a94946c7495 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antineoplastic Combined Chemotherapy Protocols
152 rdf:type schema:DefinedTerm
153 N7d049ce2d737422fb03e2feb79710e4f schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 N92bc4b1e18214da5801bb7b4cbdb2527 schema:volumeNumber 101
156 rdf:type schema:PublicationVolume
157 Nb83c384954ef4bdba387932356c87e8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Clinical Trials, Phase III as Topic
159 rdf:type schema:DefinedTerm
160 Nbe65efe6a904432f946ecb5f5c242123 rdf:first sg:person.0607771575.72
161 rdf:rest Nf06533366e4b4de6a190c5fc0d7dc954
162 Nc1160cca1b994d4a9756240f6ad09464 schema:name doi
163 schema:value 10.1038/sj.bjc.6605167
164 rdf:type schema:PropertyValue
165 Nc1e47edf18bb474da5c498229e8b4436 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Antibodies, Monoclonal, Humanized
167 rdf:type schema:DefinedTerm
168 Nc7bb00b2c9bd4e80bae37e0180d82708 rdf:first sg:person.01174312663.64
169 rdf:rest N21c5f0e6273647b8b4fba5347b685d11
170 Nd2fcd8c5bf784ddca3a78cfbe20e40ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Interferon-alpha
172 rdf:type schema:DefinedTerm
173 Ne59ee9519c204fa59618b904c2a15b82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Carcinoma, Renal Cell
175 rdf:type schema:DefinedTerm
176 Ne7fde29ac0474cf9a1e2d081910c1f31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Bevacizumab
178 rdf:type schema:DefinedTerm
179 Ned5d404bf6774e8194f81822d75e9c54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Disease-Free Survival
181 rdf:type schema:DefinedTerm
182 Nf06533366e4b4de6a190c5fc0d7dc954 rdf:first sg:person.01225701373.77
183 rdf:rest N2ff6d1f158c748149374a336276cb939
184 Nf634c063da2044af9bb8b0f9eb2683f5 rdf:first sg:person.01265262475.05
185 rdf:rest N1bff15b719444435a68b53e52a2ed655
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
190 schema:name Oncology and Carcinogenesis
191 rdf:type schema:DefinedTerm
192 sg:journal.1017082 schema:issn 0007-0920
193 1532-1827
194 schema:name British Journal of Cancer
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01054372611.40 schema:affiliation grid-institutes:grid.467855.d
198 schema:familyName Stein
199 schema:givenName K
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40
201 rdf:type schema:Person
202 sg:person.01174312663.64 schema:affiliation grid-institutes:grid.467855.d
203 schema:familyName Rogers
204 schema:givenName G
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64
206 rdf:type schema:Person
207 sg:person.01225701373.77 schema:affiliation grid-institutes:grid.5491.9
208 schema:familyName Welch
209 schema:givenName K
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225701373.77
211 rdf:type schema:Person
212 sg:person.01262712354.34 schema:affiliation grid-institutes:grid.467855.d
213 schema:familyName Green
214 schema:givenName C
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262712354.34
216 rdf:type schema:Person
217 sg:person.01265262475.05 schema:affiliation grid-institutes:grid.467855.d
218 schema:familyName Liu
219 schema:givenName Z
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265262475.05
221 rdf:type schema:Person
222 sg:person.0607771575.72 schema:affiliation grid-institutes:grid.467855.d
223 schema:familyName Moxham
224 schema:givenName T
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607771575.72
226 rdf:type schema:Person
227 sg:person.0647332044.69 schema:affiliation grid-institutes:grid.467855.d
228 schema:familyName Hoyle
229 schema:givenName M
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647332044.69
231 rdf:type schema:Person
232 sg:person.0762650054.31 schema:affiliation grid-institutes:grid.467855.d
233 schema:familyName Thompson Coon
234 schema:givenName J S
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650054.31
236 rdf:type schema:Person
237 sg:pub.10.1186/1471-2407-6-293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045174638
238 https://doi.org/10.1186/1471-2407-6-293
239 rdf:type schema:CreativeWork
240 sg:pub.10.1186/1471-2407-9-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011234840
241 https://doi.org/10.1186/1471-2407-9-34
242 rdf:type schema:CreativeWork
243 grid-institutes:grid.467855.d schema:alternateName Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
244 schema:name Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
245 rdf:type schema:Organization
246 grid-institutes:grid.5491.9 schema:alternateName Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK
247 schema:name Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...